FDA approvedMetabolic & fat loss

Tirzepatide

Mounjaro, Zepbound

REC PPT-TIRZEPATIDE // REV 2026-10-04 // assessment changes are logged, never silent

Dual GIP/GLP-1 agonist. Approved, and outperformed semaglutide in head-to-head trials.

What it is

A dual agonist acting on both GIP and GLP-1 receptors, approved as Mounjaro and Zepbound.

What it does

Combines incretin pathways to reduce appetite and improve insulin sensitivity, with weight-loss magnitudes above single-agonist GLP-1 drugs.

Does it work?

Backed by large phase 3 programmes and regulatory approval. As with semaglutide, this is prescription medicine, not a research compound, and belongs under physician supervision.

Claims vs data

Each marketing claim, tagged by what the evidence actually supports.

Greater average weight loss than semaglutide	supported
Requires no medical supervision	overreach

Reference figures

Quoted from published reference material. These are not Peptuity recommendations.

Vial10 mg

Diluent2 ml

Listed dose0.5 mg

Units / 1 ml10

FormulaC225H348N48O68

Mol. weight4813 g/mol

molecular data — PubChem CID 166567236

Open in the calculator — prefilled →

The evidence, counted

Live counts from Europe PMC and ClinicalTrials.gov.

Publications 7,505

Randomised trials 210

Clinical trials 189

Registered studies 258

7,505 publications indexed, including 210 randomised controlled trials. 258 interventional studies registered. This is a well-tested compound.

SRC // EUROPE PMC + CTGOV // "Tirzepatide" // FETCHED 2026-10-04 // 7,505 RECORDS

Most-cited literature

[01] Heart Disease and Stroke Statistics-2023 Update: A Report From the American Heart Association
Tsao CW, Aday AW, Almarzooq ZI, Anderson CAM, Arora P, Avery CL, Baker · Circulation 2023 · 4027 citations · DOI 10.1161/cir.0000000000001123
[02] Tirzepatide Once Weekly for the Treatment of Obesity
Jastreboff AM, Aronne LJ, Ahmad NN, Wharton S, Connery L, Alves B, Kiy · N Engl J Med 2022 · 2802 citations · DOI 10.1056/nejmoa2206038
[03] 2024 Heart Disease and Stroke Statistics: A Report of US and Global Data From the American Heart Association
Martin SS, Aday AW, Almarzooq ZI, Anderson CAM, Arora P, Avery CL, Bak · Circulation 2024 · 2294 citations · DOI 10.1161/cir.0000000000001209
[04] AASLD Practice Guidance on the clinical assessment and management of nonalcoholic fatty liver disease
Rinella ME, Neuschwander-Tetri BA, Siddiqui MS, Abdelmalek MF, Caldwel · Hepatology 2023 · 1874 citations · DOI 10.1097/hep.0000000000000323

Regulatory status

Formal, dated regulatory actions.

WADA — Prohibited List 2026

Not on the WADA Prohibited List

source →

Common questions

How does tirzepatide compare with semaglutide?

In head-to-head trial data tirzepatide produced greater average weight loss. Individual response and tolerability still vary, which is a clinical conversation.

Is it approved in Saudi Arabia?

Yes, as a prescription medicine under its brand names. Anything sold outside that channel is unregulated product.

Why do the incretin drugs dominate the news feed?

Because they are in active large-scale clinical development. Most compounds on this site generate almost no new registered trials; these generate hundreds.

Related compounds

FDA approved